Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 2/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575828 | 0.78 | PPARA (0.47) | — | |
| SCHEMBL4655950 | 0.78 | LMNA (0.39) | TRPM8LSS | |
| SCHEMBL14006357 | 0.78 | PRMT6 (0.47) | TRPM8 | |
| SCHEMBL4655009 | 0.77 | LMNA (0.38) | VNN1TRPM8LSS | |
| SCHEMBL4916063 | 0.77 | MCHR1 (0.44) | MCHR1EPHX2NR1H4CA12CA1 | |
| SCHEMBL4575101 | 0.76 | FFAR1 (0.41) | VNN1TRPM8 | |
| SCHEMBL4575060 | 0.76 | BCHE (0.43) | ADRB2TRPM8 | |
| SCHEMBL4575643 | 0.74 | DAGLA (0.40) | TRPM8 | |
| SCHEMBL4909563 | 0.73 | PPARD (0.49) | TRPM8 | |
| SCHEMBL4917309 | 0.73 | TRPM8 (0.41) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287477-A1 | Novel Compounds as Modulators of Ppar | KALYPSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287477-A1 | Novel Compounds as Modulators of Ppar | KALYPSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287477-A1 | Novel Compounds as Modulators of Ppar | PPARG, PPARA, PPARD | CKS1B 1416/4885SKP1 4778/4885SKP2 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.